๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sutton
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Sutton

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca25 Janssen Research & Development, LLC25 Merck Sharp & Dohme LLC12 Novartis Pharmaceuticals10 Seagen, a wholly owned subsidiary of Pfizer10
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
220 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
217
London, Sutton
2021-01-11
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
NCT04625270Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Verastem, Inc.
Phase 2
225
Edinburgh, Glasgow, London, Manchester, Sutton
2020-12-21
Active, closed
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421Neoplasms
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
AstraZeneca
Phase 1/2
702
Cambridge, Manchester, Oxford, Sutton
2020-11-12
Active, closed
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
NCT04606381Neoplasms
Janssen Research & Development, LLC
Phase 1
158
Manchester, Sutton
2020-11-10
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
308
Edinburgh, London, Sutton
2020-10-13
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
992
Brighton, Leicester, London, Maidstone, Peterborough, Plymouth, Sutton, Truro
2020-10-09
Active, closed
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 3
370
London, Manchester, Newcastle upon Tyne, Sutton
2020-10-02
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
GlaxoSmithKline
Phase 3
302
London, Plymouth, Southampton, Stoke-on-Trent, Sutton
2020-10-01
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
1,074
Edinburgh, London, Manchester, Nottingham, Sutton
2020-09-30
Active, closed
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
194
London, Sothampton, Sutton
2020-09-17
Active, closed
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
Phase 3
440
Sutton, Glasgow, Manchester
2020-09-16
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca
Phase 2
477
London, Manchester, Sutton
2020-08-18
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRฮฑ)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556Solid Tumor
Eisai Inc.
Phase 1/2
182
Belfast, Glasgow, Manchester, Preston, London, Northwood, Cardiff, Sutton
2020-08-06
Active, closed
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853Hormone-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,012
Cambridge, Guildford, Manchester, Plymouth, Sutton, Whitchurch
2020-07-13
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Sutton, Birmingham, London
2020-06-08
Active, closed
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT04379596Gastric Cancer
AstraZeneca
Phase 2
452
Cambridge, Dundee, London, Manchester, Sutton
2020-06-03
Active, closed
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
818
Aberdeen, Bournemouth, Bristol, Cardiff, Cheltenham, London, Manchester, Sutton
2020-04-16
Active, closed
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
NCT04288089Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
Eisai Inc.
Phase 1
31
London, Sutton
2020-04-01
Active, closed
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
755
Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester
2020-02-27
Active, closed
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT04042701Breast Cancer, Non-small Cell Lung Carcinoma
Daiichi Sankyo
Phase 1
115
London, Manchester, Sutton
2020-02-10
Recruiting
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT03934372Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia
Incyte Biosciences International Sร rl
Phase 1/2
70
Glasgow, Liverpool, Sutton
2020-01-29
Active, closed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 3
354
London, Sutton, Bebington, Leicester, Manchester
2020-01-10
Active, closed
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
NCT04170153Metastatic or Locally Advanced Unresectable Solid Tumors
EMD Serono Research & Development Institute, Inc.
Phase 1
161
Cambridge, Manchester, Newcastle upon Tyne, Sutton
2019-12-20
Rows per page Showing 151–175 of 220
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/sutton

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.